Autonomix Medical, Inc. Granted European Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX) announced the European Patent Office granted EP4230133 on Dec 30, 2025 for “Controlled and Precise Treatment of Cardiac Tissues.”
The patent covers systems, devices, and methods that sense autonomic/cardiac signals, map targets, and deliver closed-loop, feedback-driven neuromodulation, denervation, and/or ablation to precisely treat cardiac tissues. The grant complements U.S. Patent No. 12,369,852 and sits alongside the company’s stated IP portfolio of over 80 issued patents and 39 pending applications. The release highlights potential applications across arrhythmias, heart failure, hypertension (including renal–cardiac nerve interplay), ischemia/angina, and plaque/inflammation modulation.
Positive
- European patent EP4230133 granted on Dec 30, 2025
- Complementary U.S. protection via Patent No. 12,369,852
- IP portfolio: over 80 issued patents and 39 pending applications
- Patent cites applications across arrhythmias, heart failure, and hypertension
Negative
- No commercialization timeline or milestones disclosed in the announcement
- No clinical outcome data or trial results reported alongside the patent grant
News Market Reaction
On the day this news was published, AMIX gained 8.33%, reflecting a notable positive market reaction. Argus tracked a peak move of +42.4% during that session. Argus tracked a trough of -25.2% from its starting point during tracking. Our momentum scanner triggered 31 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $308K to the company's valuation, bringing the market cap to $4M at that time. Trading volume was exceptionally heavy at 65.5x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers in Medical Devices show mixed moves (e.g., HSCS up 12.01%, BMRA down 1.12%, MOVE down 0.25%, HSDT up 1.84%), with no clear sector trend aligning with AMIX’s pre‑news decline of 6.95%.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 23 | Strategy/IP update | Positive | -7.0% | CEO highlighted expanding IP and multi‑indication platform strategy. |
| Dec 18 | ASCO poster selection | Positive | +4.6% | ASCO GI symposium poster acceptance for pancreatic cancer pain study. |
| Nov 26 | CEO strategy segment | Positive | +10.2% | CEO Corner detailed IP protection and expansion beyond pancreatic cancer. |
| Nov 18 | Private placement | Negative | -17.4% | Dilutive $5.0M private placement with Series C warrants and pre‑funded warrants. |
| Nov 17 | Clinical PoC results | Positive | +58.2% | Post‑hoc PoC analysis showed sustained quality‑of‑life gains in pancreatic cancer. |
Recent AMIX news has mostly seen stock moves align with event tone, with one notable divergence where IP-focused communication coincided with a decline.
Over the last two months, Autonomix has combined clinical, IP, and financing updates. On Nov 17, 2025, positive pancreatic cancer PoC subgroup data was followed by a strong gain. A Nov 18 private placement and subsequent S-3/424B3 filings highlighted dilution and resale risk. CEO communications on Nov 26 and Dec 23 emphasized platform IP and multi-indication strategy. Today’s European patent grant extends that IP narrative into cardiology alongside existing oncology work.
Regulatory & Risk Context
An effective Form S-3 filed on Nov 26, 2025 registers 13,504,998 warrant shares for resale from a November 2025 PIPE. While Autonomix receives no proceeds from resales, full cash exercise of the common warrants could deliver up to $7.7 million and significantly increase the share count. A related 424B3 on Dec 12, 2025 reiterates potential dilution and share price pressure from these registered resales.
Market Pulse Summary
The stock moved +8.3% in the session following this news. A strong positive reaction aligns with Autonomix’s emphasis on building a differentiated IP moat. The new European patent for cardiac tissue treatment extends protection beyond pancreatic cancer into cardiology indications, complementing the recently issued U.S. patent and prior IP-focused CEO updates. However, investors have faced significant dilution from the November $5.0 million PIPE, registered 13.5M resale shares, and multiple capital facilities, which could cap sustainability if enthusiasm fades.
Key Terms
neuromodulation medical
denervation medical
ablation medical
arrhythmias medical
myocardial infarction medical
renal denervation medical
autonomic medical
radiofrequency medical
AI-generated analysis. Not financial advice.
With over 80 issued patents and 39 pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulation
Newly granted patent further strengthens the Company’s strategic position in a multi-billion-dollar market opportunity, unlocking potential across cardiovascular, renal, and other high-burden diseases
THE WOODLANDS, TX, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the European Patent Office (EPO) has granted Patent No. EP4230133 (the ‘133 patent), titled, “Controlled and Precise Treatment of Cardiac Tissues.” The newly granted ‘133 patent covers systems, devices, and methods that sense autonomic/cardiac signals, map targets, and then deliver therapy with closed-loop feedback to precisely treat cardiac tissues by performing feedback-driven neuromodulation, denervation, and/or ablation of tissues.
“This European patent represents another important milestone in strengthening and expanding the global IP foundation behind our breakthrough technology platform, commented Brad Hauser, CEO of Autonomix. This patent builds on and broadens the protection provided by our recently issued U.S. Patent No. 12,369,852, further enhancing our ability to provide precision nerve-targeted therapies that have the potential to transform treatment in key, high-growth areas of cardiology, including renal denervation for hypertension, arrhythmia management, heart failure, and refractory angina, while reducing complications.”
In particular, the ‘133 patent relates to systems, devices, and methods for performing precise treatment, mapping, and/or testing of tissues and for identifying, localizing, monitoring, and mapping neural traffic near targeted regions. Further, the patent highlights applications across arrhythmias (atrial & ventricular), ischemia/angina (including refractory angina pain), coronary spasm, myocardial infarction risk modulation, heart failure, hypertension (including interplay with renal-cardiac nerves), and plaque/inflammation modulation, where local, feedback-guided denervation or modulation may reduce dependence on systemic beta blockade and its side effects.
Autonomix’s first-in-class technology constitutes a platform with the potential to address dozens of indications in multiple high-need therapeutic areas, including cardiology and resistant hypertension or high blood pressure, interventional pain management, pulmonary and gastrointestinal disorders, and more. For more information about the Company’s technology, please visit autonomix.com.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
What did Autonomix (AMIX) announce on December 30, 2025?
How does the EP4230133 patent complement Autonomix’s U.S. rights (AMIX)?
What indications does the newly granted Autonomix patent (AMIX) mention?
How extensive is Autonomix’s IP portfolio reported with the EP4230133 grant?
Will the EP4230133 patent immediately change Autonomix’s commercial status (AMIX)?
